Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.

No abstract available

COI Statement

Competing interests: LB: Consultancy; AstraZeneca, Janssen-Cilag, Beigene, Abbvie; research grants; AstraZeneca, Janssen-Cilag, DR-W: Consultancy: Abbvie, AstraZeneca, BeiGene, Janssen-Cilag, GL: Consultancy; AstraZeneca, Janssen-Cilag, Beigene, AC: Consultancy: AstraZeneca, Janssen-Cilag, Abbvie, XT: Consultancy: Abbvie, AL: Consultancy: Janssen-CilagCT: Consultancy: Janssen-Cilag, BeiGene, AstraZeneca, Abbvie, JH: Consultancy: Novartis, Abbvie, AstraZeneca, Servier, JC: Consultancy: Janssen-Cilag, Takeda and JazzPharma. Travel grants: MSD, Gilead, Novartis, Janssen-Cilag, Pfizer; Sandoz, Abbvie, SC: Consultancy and travel grants; AstraZeneca, Janssen-Cilag, Beigene, Abbvie; research grants; AstraZeneca, Janssen-Cilag.

References:

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720–48.
Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti M, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol. 2014;1:e74–84.
Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015;125:856–9.
Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, et al. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica. 2019;104:360–9.
Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, et al. No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica. 2018;103:e158–61.

Article info

Journal issue:

Volume: not provided
Issue: not provided

Doi:

10.1038/s41375-025-02555-0

More resources:

Nature Publishing Group

Full Text Sources

Paid

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.

No abstract available

COI Statement

References:

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720–48.
Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti M, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol. 2014;1:e74–84.
Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015;125:856–9.
Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, et al. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica. 2019;104:360–9.
Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, et al. No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica. 2018;103:e158–61.